Overview

Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals